The 5-Minute Rule for Targeting angiogenesis for patients with unresectable Preclinical studies with LEITP-1009 are underway. In July 2021, Pharma, Mar announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Company (EMA) has actually provided its favorable opinion for Orphan Drug Classification to Zepzelca (lurbinectedin) for